Creutzfeldt-Jakob Disease

FDA committee meeting focused on transmissible spongiform encephalopathies

Published in Blood Weekly, April 14th, 2005

An update on transmissible spongiform encephalopathies (TSEs), including variant Creutzfeldt-Jakob Disease (vCJD), the human form of "mad cow" disease, was a key topic at the U.S. Food and Drug Administration's Blood Products Advisory Committee meeting in Gaithersburg, Maryland.

Issues such as the number of people that could be harboring vCJD as carriers, the impact on the blood supply and new risk reduction measures were addressed. Pall Corporation (PLL) presented an overview of the latest research on its prion reduction technology as a new risk reduction measure to help prevent transfusion transmission of infectious prions that can cause vCJD. The company expects to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry